Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Harpoon Therapeutics, Inc. (HARP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.7390+0.0310 (+4.38%)
At close: 04:00PM EST
0.7400 +0.00 (+0.14%)
After hours: 07:34PM EST
Advertisement

Harpoon Therapeutics, Inc.

131 Oyster Point Boulevard
Suite 300
South San Francisco, CA 94080
United States
650 443 7400
https://www.harpoontx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees86

Key Executives

NameTitlePayExercisedYear Born
Ms. Julie M. Eastland M.B.A.Pres, CEO & Director339.67kN/A1964
Dr. Natalie R. Sacks M.D.Consultant751.79kN/A1965
Ms. Georgia L. ErbezConsultant628.26kN/A1967
Dr. Holger Wesche Ph.D.Chief Scientific OfficerN/AN/A1968
Ms. Wendy ChangSr. VP of HRN/AN/AN/A
Ms. Rachael LesterSr. VP of Bus. Devel. & Corp. StrategyN/AN/AN/A
Dr. Banmeet Anand Ph.D.Sr. VP of Translational MedicineN/AN/AN/A
Dr. Luke N. Walker M.D.Chief Medical OfficerN/AN/A1972
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Corporate Governance

Harpoon Therapeutics, Inc.’s ISS Governance QualityScore as of November 28, 2022 is 7. The pillar scores are Audit: 4; Board: 7; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement